BAY 59-3074
Jump to navigation
Jump to search
| File:BAY59-3074.svg | |
| Gene therapy | |
|---|---|
| Clinical data | |
| Physiological data | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C18H13F6NO4S |
| Molar mass | 453.35 g/mol |
BAY 59-3074 is a drug which is a cannabinoid receptor partial agonist developed by Bayer AG. It has analgesic effects and is used in scientific research. It is orally active in animals, and has modest affinity for both CB1 and CB2 receptors, with Ki values of 48.3nM at CB1 and 45.5nM at CB2.[1][2]
References
- ↑ De Vry J, Denzer D, Reissmueller E, Eijckenboom M, Heil M, Meier H, Mauler F. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects. Journal of Pharmacology and Experimental Therapeutics. 2004 Aug;310(2):620-32. PMID 15140913
- ↑ De Vry J, Jentzsch KR. Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. European Journal of Pharmacology. 2004 Nov 28;505(1-3):127-33. PMID 15556145
Categories:
- Articles with short description
- Pages with broken file links
- Drugs with non-standard legal status
- Infobox-drug molecular-weight unexpected-character
- Pages using infobox drug with unknown parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Cannabinoids